Search
for
Sort by
Research 331–360 of 1000+
- POS0080 TOFACITINIB TREATMENT IN CHILDREN WITH RHEUMATIC DISEASES: SINGLE-CENTER EXPERIENCE
- 1108 Comparison of ruxolitinib and a collagen-targeted PTH-based hair cycle stimulant on hair follicle counts and hair growth in the C3H/HeJ engrafted mouse model of alopecia areata
- Circulating MicroRNA Signatures in Severe Alopecia Areata: Diagnostic Discrimination, Pathway Analysis, and Therapeutic Implications
- Alopecia Areata: Pathogenesis, current treatments, and future perspectives
- Hair follicle stem cells and the collapse of self-tolerance in alopecia: the interplay of barrier function, the microbiome, and immunity
- Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
- Miscellaneous Topics in Disorders of Endocrine Glands
- Serum Level of Survivin in Patients with Alopecia Areata and its Association with Disease Severity and Progression
- The JAK/STAT signaling pathway: from bench to clinic
- ES01.01 Chemotherapy is Strictly Additive to Immunotherapy
- Short-Chain Fatty Acids from <i>Cutibacterium acnes</i> Activate Both a Canonical and Epigenetic Inflammatory Response in Human Sebocytes
- Netherton syndrome subtypes share IL-17/IL-36 signature with distinct IFN-α and allergic responses
- Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis
- Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
- Treating Alopecia Areata: Current Practices Versus New Directions
- The common regulatory pathway of COVID-19 and multiple inflammatory diseases and the molecular mechanism of cepharanthine in the treatment of COVID-19
- Pimecrolimus interferes the therapeutic efficacy of human mesenchymal stem cells in atopic dermatitis by regulating NFAT-COX2 signaling
- Alopecia areata: Time for position statement to include new systemic therapeutic advances
- Alopecia Areata - Current and Emerging Therapies
- Targeted immunotherapy for hair regrowth and regeneration
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- 014 Tyrosine Kinase 2 Inhibition Ameliorates the Phenotype of Lesional Alopecia Areata Scalp Skin Ex Vivo, and Reverses the Induction of Human Alopecia Areata in a Humanized Mouse Model
- Modern dermatology brings treatment even for alopecia areata
- The pharmacology of methotrexate
- Erlotinib-related Severe Hair Loss with Severe Exanthematous Drug Eruption: A Case Report
- Leflunomide: an unlikely trigger and mechanistically a beneficial drug for alopecia areata
- Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- Deciphering the Complex Immunopathogenesis of Alopecia Areata